May. 15 at 11:26 PM
$SLDB 750M,
$RGNX 370M For what exactly?
RGX-202 Phase 3 just hit primary endpoint — 93% of patients above 10% microdystrophin expression p<0.0001. Statistically significant correlation with functional improvement. CT domain differentiation. 2+ years safety data.
SGT-003 has biomarkers and a Phase 3 that just dosed its first patient — no NSAA, no timed tests published. Results won't come before 2028 at best.
Market punishing RGNX on cash and FDA execution — fair. But
$100M AbbVie coming Q2, wet AMD readout Q4. You're paying ~
$120M above cash for all of that.
SLDB you're paying
$370M above cash for Phase 3 data years away.
Make it make sense.
$SLDB $DMD.X
